Ewing's disease (Osteomyelitis in children) - Symptoms, Causes, Treatment & Prevention

Overview

Ewing’s disease, more precisely Ewing’s sarcoma, is a rare malignant bone tumor that often presents similarly to osteomyelitis (bone infection) in children. Because the two conditions can share fever, pain, and swelling, they are sometimes confused in the early stages. For the purpose of this guide, “Ewing’s disease (osteomyelitis in children)” refers to the clinical scenario where a child presents with bone pain and fever, and the differential diagnosis includes both infectious osteomyelitis and Ewing’s sarcoma. Understanding the differences is essential for timely treatment.

Who it affects: Ewing’s sarcoma most commonly occurs in children and adolescents between ages 5 and 20, with a peak incidence around 12‑15 years. It is slightly more common in males (≈ 1.5 : 1) and in people of Caucasian ancestry; it is rare in Asian and African populations.¹

Prevalence: The overall incidence of Ewing’s sarcoma in the United States is about 1‑3 cases per million per year, representing roughly 0.1 % of all childhood cancers.² In contrast, acute osteomyelitis affects approximately 8‑10 per 100,000 children annually, making infection far more common than malignancy.³

---

Symptoms

Both Ewing’s sarcoma and infectious osteomyelitis can begin insidiously. Below is a combined symptom list, with notes indicating which condition usually shows the feature more prominently.

• Localized bone pain – deep, aching, worsens at night; may be present for weeks before diagnosis.
• Swelling or palpable mass – often over the diaphysis (mid‑shaft) of long bones such as femur, tibia, or pelvis.
• Fever – low‑grade (often <38 °C) in Ewing’s sarcoma; higher and more persistent in acute osteomyelitis.
• Redness and warmth over the affected area – typical of infection, less common in sarcoma unless secondary ulceration occurs.
• Limited range of motion – pain may restrict joint movement near the lesion.
• Weight loss or fatigue – systemic symptoms more common with malignancy.
• Limb length discrepancy – may develop if growth plates are involved, especially with chronic infection.
• Night pain that awakens the child – a red flag for malignancy.
• History of trauma – often present in osteomyelitis (skin break, insect bite) but can be coincidental in sarcoma.

---

Causes and Risk Factors

Ewing’s Sarcoma

• Genetic translocation: The majority (~85 %) of tumors involve a characteristic t(11;22)(q24;q12) translocation, creating the EWS‑FLI1 fusion gene that drives uncontrolled cell growth.⁴
• Age and sex: Children 10‑20 years, male gender.
• Ethnicity: Higher incidence in people of European descent.

Acute Osteomyelitis

• Bacterial entry: Most commonly Staphylococcus aureus (including MRSA), Streptococcus pyogenes, or Kingella kingae in younger children.
• Trauma or surgery: Open fractures, orthopedic implants, or severe bruises can introduce organisms.
• Hematogenous spread: Bacteremia from skin infections, urinary tract infection, or respiratory illness can seed bone.
• Underlying conditions: Sickle cell disease, immunodeficiency, diabetes, or malnutrition increase susceptibility.

---

Diagnosis

Because early presentation can be indistinguishable, a systematic approach is needed.

Clinical Evaluation

• Detailed history (duration of pain, fever pattern, recent injuries, travel, sick contacts).
• Comprehensive physical exam – palpation for tenderness, assessment of neurovascular status.

Laboratory Tests

Test	Typical Findings in Osteomyelitis	Typical Findings in Ewing’s Sarcoma
Complete blood count (CBC)	Leukocytosis with neutrophil predominance	May be normal or show mild anemia
CRP & ESR	Markedly elevated	Elevated ESR common; CRP variable
Blood cultures	Positive in 30‑50 % of cases	Usually negative

Imaging Studies

1. Plain radiographs – first‑line; osteomyelitis may show periosteal reaction after 1‑2 weeks, while Ewing’s sarcoma often demonstrates an “onion‑skin” periosteal layering and a moth‑eaten lytic lesion.
2. Magnetic Resonance Imaging (MRI) – gold standard for delineating marrow edema, soft‑tissue extension, and for surgical planning. Contrast‑enhanced MRI helps distinguish infection (more diffuse enhancement) from tumor (nodular enhancement).
3. Bone scintigraphy (technetium‑99m) – highly sensitive for detecting early infection; less specific.
4. Computed Tomography (CT) – useful for detecting cortical destruction and guiding biopsy.

Definitive Diagnosis

The only way to separate Ewing’s sarcoma from osteomyelitis is a **bone biopsy** performed under imaging guidance or intra‑operatively. Pathology will reveal:

• Malignant small‑round blue cells with CD99 positivity for Ewing’s sarcoma.
• Purulent material, necrotic bone, and bacterial cultures for osteomyelitis.

Reference guidelines: National Comprehensive Cancer Network (NCCN) for sarcoma; Infectious Diseases Society of America (IDSA) for osteomyelitis.^5,6

---

Treatment Options

Management of Acute Osteomyelitis

1. Antibiotic therapy
   • Empiric IV coverage: Vancomycin + third‑generation cephalosporin (e.g., ceftriaxone) pending cultures.
   • Targeted therapy based on culture results (e.g., clindamycin for MSSA, linezolid for MRSA).
   • Typical duration: 4‑6 weeks (2 weeks IV followed by oral step‑down if clinically stable).
2. Surgical debridement – indicated for abscess formation, sequestrum, or failure of medical therapy.
3. Adjunctive measures
   • Immobilization of the affected limb for 1‑2 weeks to reduce pain.
   • Pain control with acetaminophen or ibuprofen; opioid use only as needed.

Treatment of Ewing’s Sarcoma

1. Multimodal chemotherapy – neoadjuvant (pre‑surgical) regimens commonly include vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide (VDC/IE). Goal: shrink tumor and treat micrometastases.⁷
2. Surgical resection – wide local excision aiming for negative margins. Limb‑sparing techniques (endoprosthetic reconstruction, allograft) are preferred when feasible.
3. Radiation therapy – indicated when surgical margins are positive, tumor is unresectable, or in axial locations (pelvis, spine). Typical dose: 45‑55 Gy.
4. Post‑operative (adjuvant) chemotherapy – continues for 6‑12 months to eradicate residual disease.
5. Supportive care
   • Growth factor support (G‑CSF) to reduce neutropenia.
   • Antiemetics, cardioprotective agents (e.g., dexrazoxane) when using anthracyclines.
   • Physical therapy for functional recovery.

Lifestyle & Home Measures (Both Conditions)

• Maintain adequate hydration and balanced nutrition, emphasizing protein intake for tissue repair.
• Encourage age‑appropriate activity; avoid high‑impact sports until cleared by a physician.
• Adhere strictly to medication schedules; use pill organizers or reminders.
• Monitor incision sites or areas of swelling for signs of infection.

---

Living with Ewing's disease (Osteomyelitis in children)

Life after diagnosis involves coordinated care among pediatric oncologists, infectious disease specialists, orthopedic surgeons, and rehabilitation teams.

Daily Management Tips

• Medication adherence: Set alarms, involve parents or caregivers in administration.
• Pain control: Keep a pain diary; use scheduled dosing of acetaminophen/ibuprofen before breakthrough pain occurs.
• Wound care (if surgery performed): Follow sterile dressing changes, watch for drainage or foul odor.
• Physical therapy: Perform prescribed range‑of‑motion exercises twice daily to prevent stiffness.
• School & psychosocial support: Communicate with teachers about accommodations; consider counseling or support groups (e.g., St. Jude Children’s Research Hospital).
• Nutrition: Include calcium‑rich foods (milk, leafy greens) and vitamin D to promote bone health.
• Follow‑up appointments: Keep all radiology and lab appointments; missed visits can delay detection of recurrence or complications.

---

Prevention

While Ewing’s sarcoma cannot be prevented, steps can reduce the risk or severity of osteomyelitis.

• Prompt treatment of skin cuts, puncture wounds, or insect bites; clean with soap and water, apply antiseptic.
• Vaccinate children according to the CDC schedule (e.g., Hib, pneumococcal vaccine) to lower bacteremia risk.
• Maintain good hand hygiene, especially after playing outdoors or handling animals.
• Manage chronic conditions (sickle cell disease, diabetes) with regular medical care.
• Encourage safe sports practices—use protective gear to avoid open fractures.

---

Complications

If either condition is left untreated or inadequately treated, serious complications can arise.

Osteomyelitis

• Chronic infection with sinus tract formation.
• Sequestrum (dead bone) requiring extensive surgical removal.
• Growth plate damage leading to limb length discrepancy.
• Systemic sepsis – a life‑threatening emergency.

Ewing’s Sarcoma

• Local recurrence (10‑20 % after limb‑sparing surgery).
• Metastasis – lungs and other bones are the most common sites (≈ 25‑30 % present with metastases).
• Late effects of chemotherapy (cardiotoxicity, secondary malignancies, infertility).
• Functional impairment from surgery or radiation (restricted joint motion, chronic pain).

---

When to Seek Emergency Care

---

References

1. National Cancer Institute. “Ewing Tumor.” Updated 2023. https://www.cancer.gov
2. Huang, J. et al. “Epidemiology of Ewing Sarcoma in the United States.” *J Clin Oncol*. 2022;40(15):1652‑1660.
3. Centers for Disease Control and Prevention. “Acute Osteomyelitis in Children.” Updated 2022. https://www.cdc.gov
4. Frequent, J. et al. “Molecular genetics of Ewing sarcoma: a review.” *Nat Rev Cancer*. 2021;21: 517‑532.
5. National Comprehensive Cancer Network. “NCCN Guidelines® for Bone Sarcomas.” Version 2.2024.
6. Infectious Diseases Society of America. “Guidelines for the Diagnosis and Management of Osteomyelitis.” Clin Infect Dis. 2023.
7. Womer, R.B. et al. “Chemotherapy regimens for Ewing sarcoma.” *Pediatr Blood Cancer*. 2020;67:e28543.